TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance with a 25% YoY revenue increase and improved gross margins. Despite regulatory and market challenges, the company shows resilience with reduced net loss and strategic initiatives for product development. The lack of guidance or shareholder return details is a concern, but the financial metrics and growth potential in Europe suggest a positive outlook. The stock price is likely to experience a positive movement of 2% to 8% over the next two weeks, assuming a neutral market cap impact.
Key Financial Performance
Revenue Revenue for Q1 2026 was $15.2 million, representing a 25% increase year-over-year. This growth was driven by strong demand for the company's OviTex and OviTex PRS product lines.
Gross Margin Gross margin improved to 72% in Q1 2026, up from 68% in Q1 2025. The improvement was attributed to better operational efficiencies and a favorable product mix.
Operating Expenses Operating expenses for Q1 2026 were $12.5 million, a 15% increase compared to Q1 2025. The rise was primarily due to higher investments in sales and marketing efforts.
Net Loss Net loss for Q1 2026 was $2.8 million, compared to $3.5 million in Q1 2025. The reduction in net loss was due to higher revenue and improved gross margins.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges potential risks related to regulatory filings and compliance, which could impact product development and pipeline opportunities.
Market and Sales Challenges: Statements regarding sales and marketing strategies suggest potential challenges in achieving desired market penetration or sales targets.
Forward-Looking Uncertainties: Forward-looking statements highlight uncertainties that could lead to material differences in actual results, impacting strategic objectives and financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Product Development: Statements regarding product development, pipeline opportunities, sales and marketing strategies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arnt Lake
CFO Corporate
COO Jim
Caitlin Cronin
Canaccord Genuity
Contact Officer
Corporate Secretary
Cronin Canaccord
Director Roberto
Division Ian
Division OBrien
Division PM
EDT day
Genuity Corp
Hagen VP
Ian Arnt
Instructions today
Jim Hagen
LLC Sarcone
Marketing Caitlin
OBrien Piper
Officer Antony
PM EDT
Piper Sandler
Relations Contact
Research Division
Roberto Cuca
Sandler Co
Secretary COO
day Conference
TELA Transcript
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary reveals strong financial performance with a 25% YoY revenue increase and improved gross margins. Despite regulatory and market challenges, the company shows resilience with reduced net loss and strategic initiatives for product development. The lack of guidance or shareholder return details is a concern, but the financial metrics and growth potential in Europe suggest a positive outlook. The stock price is likely to experience a positive movement of 2% to 8% over the next two weeks, assuming a neutral market cap impact.
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reflects mixed signals. While there are improvements in losses and cash flexibility, the reduced guidance and uncertainties due to organizational changes and external factors like weather impact sentiment negatively. The Q&A highlighted management's cautious approach and lack of clarity in some responses, further contributing to a neutral outlook. The absence of strong positive catalysts or partnerships limits the potential for a significant stock price increase.
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed performance, with stable gross margins and reduced losses but lowered guidance for 2025, indicating potential challenges. The Q&A highlights uncertainties, particularly with unclear management responses and the need for refinancing and equity raises, suggesting financial strain. Despite some positive growth in Europe and a strong sales force, the lack of precise future growth details and a lowered guidance contribute to a negative sentiment, likely impacting the stock price negatively in the short term.
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call indicates strong financial performance with reduced losses and consistent sales growth. The Q&A section supports this with plans for sales force expansion and strategic focus on new product launches and market positioning. Despite some expenses rising, the overall financial health appears stable. Additionally, management's confidence in meeting guidance and increased focus on patient-centric culture and reinforced tissue matrix contracts suggest positive future prospects. The lack of any major risks or uncertainties in management responses further supports a positive sentiment.
TELA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
